Soleno Therapeutics Files 8-K on Security Holder Vote Matters

Ticker: SLNO · Form: 8-K · Filed: 2025-06-06T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: SLNO

TL;DR

SOLENO THERAPEUTICS (SLNO) filed an 8-K for a shareholder vote. Details TBD.

AI Summary

On June 5, 2025, Soleno Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of its security holders. The filing does not specify the nature of the vote or any associated details like dates of meetings or specific proposals.

Why It Matters

This filing indicates that Soleno Therapeutics is seeking approval from its shareholders on certain matters, which could impact corporate governance or strategic decisions.

Risk Assessment

Risk Level: low — The filing is procedural and does not contain information that immediately suggests significant financial or operational risk.

Key Players & Entities

FAQ

What specific matters are being submitted for a vote by Soleno Therapeutics' security holders?

The filing states that matters are being submitted to a vote of security holders, but the specific nature of these matters is not detailed in the provided excerpt.

When is the vote expected to take place?

The filing does not specify the date of the vote or any associated meeting.

Has Soleno Therapeutics provided any preliminary information or recommendations regarding the upcoming vote?

This 8-K filing does not include any preliminary information or recommendations from the company regarding the vote.

What is the significance of filing an 8-K for a submission of matters to a vote?

Filing an 8-K for such matters is a requirement to inform the public and shareholders about significant corporate actions that require shareholder approval.

Does this filing indicate any changes in the company's board of directors or executive management?

The filing pertains to a vote of security holders and does not explicitly mention changes in board or executive management in the provided text.

From the Filing

0001193125-25-137047.txt : 20250606 0001193125-25-137047.hdr.sgml : 20250606 20250606160630 ACCESSION NUMBER: 0001193125-25-137047 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250605 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250606 DATE AS OF CHANGE: 20250606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 251030626 BUSINESS ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 8-K 1 d939581d8k.htm 8-K 8-K SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-06-05 2025-06-05     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 5, 2025     SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-36593   77-0523891 (State or other jurisdiction of incorporation)   (Commission File No.)   (IRS Employer Identification Number) 100 Marine Pkwy , Suite 400 Redwood City , CA 94065 (Address of principal executive offices) (650) 213-8444 (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbols   Name of each exchange on which registered Common Stock, $0.001 par value   SLNO   NASDAQ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       ITEM 5.07 Submission of Matters to a Vote of Security Holders. On June 5, 2025, Soleno Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders. Of the 49,908,303 shares of common stock outstanding as of April 15, 2025, the record date, 47,273,966 shares of common stock were represented at the meeting in person or by proxy, constituting approximately 94.7% of the outstanding shares of common stock entitled to vote and constituting a quorum for the transaction of business. The stockholders of the Company voted on the following items at the Annual Meeting:   1. To elect two Class II directors to serve until the 2028 A

View on Read The Filing